学校首页 | 学院首页 
         
赵明

姓名:赵明

性别:女

职称:教授

 

招生院所:药学院

招生类型:科学学位(博) 科学学位(硕)专业学位(硕)

招生专业:药物化学(博) 药物化学(硕)药学(硕)

研究方向名称:多肽及小分子纳米药物研究

电子信箱:

个人简介

1960年生于北京,1995年毕业于北京医科大学药学院,获理学博士学位。1997年年被北京医科大学聘为副教授,2001年被北京大学药学院聘为教授,博士生导师。2006年至今为北京市特聘教授/多肽及小分子药物北京市重点实验室主任;2006-2012年为首都医科大学化学生物学与药学院副院长、2012-2014年为首都医科大学化学生物学与药学院常务副院长,2014年-至今为首都医科大学化学生物学与药学院院长,2007年为美国North Carolina大学访问教授、2009年至今为内源式预防药物教育部工程研究中心主任。2013年至今为生物医用材料北京实验室副主任,高雄医学大学客座教授。 赵明致力于“基于氨基酸的寡肽药物”、“基于氨基酸的糖胺药物”等特色研究。主持完成了“1035”、“985”、“973”、“十一五”重大新药创制、国家自然科学基金(4项)、教育部博士点基金等研究项目。已发表国外SCI论文160余篇,其中11篇被J MATER CHEM B等杂志选为封面文章,申请国家发明专利690余项(授权380余项);获7项省部级科技进步奖。除参编13部国内专著外,受Wiley出版社邀请于2009年全球发行1部关于药物的生物分析的英文专著,被Wiley出版社推荐为该领域权威著作,并被国外前40名高校中的12所学校,如Stanford、Cambridge等大学图书馆收藏;英国University" of East Anglia的Dr. Gerd Wagner 特别撰写书评发表在ChemMedChem上。由于抗骨质疏松新药研究的成绩, INTECH出版社邀请他为即将出版的New Findings in Osteoporosis (骨质疏松的新发现) 撰写了Modification of sex hormones with RGD-peptide: A strategy of improving HRT and other secondary osteoporosis therapy。在这本新书中, 这是唯一涉及抗骨质疏松新药研究的章节。此外,发表在英国化学会MedCheCom上的研究结果被BIONITY. COM网站报道、受国际杂志Expert Opin. Ther. Pat邀请对国际同行的专利进行专家评述、发表在ACS-NANO的文章被 ACS News Service Weekly PressPac: September 04, 2013报道,国内外媒体纷纷转载,发表在Nanoscale, Journal of Materials Chemistry, Medchemcomn,的药物研究的文章受邀作为封底文章。现为JMC、EJMC等刊物的审稿人,2010年被JMC评为Top tier reviewer。国际知名度逐步提高。 1986年至今一直从事高等药学教育,站在教学第一线。独立承担3门本科生理论课和实验课、4门研究生理论课和实验课,理论授课240学时/年,实验课210学时/年。此外,承担药学专业实验课的管理和改革,实施精品药学教育,突出本科生和研究生实现大型仪器的操作,培养真才实学的创新和创业药学人才针对新药研发特点,坚持融合药物设计、合成、分析、活性筛选及药物作用机理研究到研究生的学位论文中,使硕士生的研究产出国家发明专利,博士生的研究产出国外SCI论文。研究生得到了全面训练。2002年至今培养50余名博士生;100余名硕士生。获2001年北京市教学成果一等奖和国家教学成果二等奖、2009年北京市教育教学成果二等奖、2010年获首都教育先锋科技创新个人、“三八”红旗奖章、2013年北京市教育教学成果二等奖。2015年获北京市高等学校教学名师,2016年北京市高层次创新创业人才支持计划领军人才,2017年获北京市优秀教师,2018年获北京市师德榜样。2019年获首都劳动奖章。 积极推动成果转化。5种产品上市、1个一类新药获临床批文、1个二类新药。转让专利及技术11项,为企业带了直接或间接效益3000万;其中一项被美国FDA批准进入期Ⅱ临床(IND132347),目前已完成二期临床试验。上海医药集团股份有限公司已投资2.6亿元人民币,获得授权开发中国大陆市场,有望成为治疗脑卒中的新型溶栓药物。

教育经历

1979-1983  北京医科大学, 药学院, 学士;

1991-1995  北京医科大学, 药学院, 博士;

工作经历

2019-至今  首都医科大学药学院党总支书记

2017-2019  首都医科大学药学院党委书记

2014-2018  首都医科大学化学生物学与药学院/药学院,院长

2013-至今 生物医用材料北京实验室副主任

2012-2014  首都医科大学化学生物学与药学院,常务副院长

2006-2012  首都医科大学化学生物学与药学院,副院长

2009-至今 内源式预防药物教育部工程研究中心主任

2006-至今  北京市特聘教授,多肽及小分子药物北京市重点实验室主任

2001-2006  北京医科大学, 药学院教授, 博导;

1997-2001  北京医科大学, 药学院副教授;

重要学术论文

2020

Guanyu Li, Tong Wang, Xiaoyi Zhang, Shurui Zhao, Yaonan Wang, Jianhui Wu, Shiqi Peng*,Ming Zhao*. Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation. Drug Design, Development and Therapy.2020:14 2187–2197.

Mengyu Hou, Manjie Lv, Xiaoyi Zhang, Yaonan Wang, Shurui Zhao, Jianhui Wu, Ming Zhao*, Shiqi peng*. Discovery of novel 6S/12aS-heptachpyridone capable of targeting thrombus and inhibiting thrombosis in vivo. Journal: Bioorganic & Medicinal Chemistry Letters. Volume 30, Issue 19, 1 October 2020, 127440

Xiaoyi Zhang,Yixin Zhang,Yaonan Wang,Jianhui Wu,Haiyan Chen,Ming Zhao*,Shiqi Peng*. Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine. International journal of nanomedicine, (2020): 465-481

Xiaoyi Zhang1,2, Jinhuan Zhang1,2, Wenchao Liu1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Ming Zhao1,2,3* & Shiqi Peng1,2*。Exploring the action of RGDV‑gemcitabine on tumor metastasis, tumor growth and possible action pathway. Scientific Reports | (2020) 10:15729  

2019  

Guanyu Li, Yi Ren, Xiaoyi Zhang, Shurui Zhao, Yaonan Wang, Jianhui Wu, Shiqi Peng*, Ming Zhao*. 13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein. Onco Targets Ther 2019 Dec 5;12:10651-10662

Wenchao Liu1,2 Yujia Mao1,2 Xiaoyi Zhang1,2 Yaonan Wang1,2 Jianhui Wu 1,2 Shurui Zhao1,2 Shiqi Peng 1,2 Ming Zhao*1.RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine. International Journal of Nanomedicine 2019:14 7263–7279

Shurui Zhao,Ze Li,Fei Huang,Jianhui Wu,Lin Gui,Xiaoyi Zhang,Yaonan Wang,Xiaozhen Wang,Shiqi Peng,Ming Zhao*. Nano-scaled MTCA-KKV: for targeting thrombus,releasing pharmacophores, inhibiting thrombosisand dissolving blood clots in vivo. International Journal of Nanomedicine 2019:14 4817–4831 

Jianhui Wu,Yue Cui,Xiaoyi Zhang,Lin Gui,Yaonan Wang,Shiqi Peng,Ming Zhao,*. BCESA: a nano-scaled intercalator capable of targeting tumor tissue and releasing antitumoral β-carboline-3-carboxylic acid. International Journal of Nanomedicine 2019:14 3027–3041

Juan Feng, Meng Zhou, Xuanzi Lin, An Lu, Xiaoyi Zhang, and Ming Zhao*.Base-Mediated [3 + 4]-Cycloaddition of Anthranils with Azaoxyallyl Cations: A New Approach to Multisubstituted Benzodiazepines. Org. Lett. 2019, 21, 6245−6248. 

Shuangling Chen , Zidong Peng, Yuji Wang , Jianhui Wu, Ran An , Rongrong Miao , Ming Zhao , * , Shiqi Peng ,Development and activity evaluation of Arg-Gly-Asp-containing antithrombotic conjugate,Journal of Molecular Structure 1198 (2019) 126816 

2018  

Yaonan Wang, Haiyan Chen, Xiaoyi Zhang, Jianhui Wu,Qiqi Feng, Shiqi Peng,, Ming Zhao.* Dimethyl 2,2′-[2,2′-(ethane-1,1-diyl)bis(1H-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect. International Journal of Nanomedicine 2018:13 7835–7844 

Jianhui Wu, a§ Haimei Zhu, a§ Guodong Yang,a Jianhong He, *c Yuji Wang, a Shurui Zhao,a Xiaoyi Zhang,a Lin Gui,a Ming Zhao*a,b & Shiqi Peng*a, Design and synthesis of nano-scaled IQCA-TAVV as a delivery capable of anti- platelet activation, targeting arterial thrombus and releasing IQCA. International Journal of nanomedicine  2018 , 13 :1139-1158  

Ze Li, Fei Huang, Jianhui Wu, Lin Gui, Xiaoyi Zhang, Yaonan Wang, Shurui Zhao, Xiaozhen Wang, Shiqi Peng*, and Ming Zhao*. Heptapeptide based modification leading to enhancing the action of MTCA on activated platelets, P-selectin, GPIIb/IIIa.  Future Medicinal Chemistry. 2018 , 10 (16) :1957-1970 

Haiyan Chen, An Lu, Xiaoyi Zhang, Lin Gui, Yaonan Wang, Jianhui Wu, Hua Feng, Shiqi Peng* and Ming Zhao* .Design and development of ICCA as dual inhibitor of GPIIb/IIIa and P-selectin receptors.Drug Design, Development and Therapy. 2018; 12: 2097–2110.

Haimei Zhu, Yuji Wang, Ce Song, Qiqi Feng, Jianhui Wu, Shurui Zhao, Lin Gui, Xiaoyi Zhang, Ming Zhao and Shiqi Peng. Docking of THPDTPI: to explore P-selectin been a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent,\. Oncotarget, 2018 , 9 (1) :268-281 

Haiyan Chen,Wenjing Wang,Xiaoyi Zhang,Shan Liu,Yaonan Wang,Haimei Zhu,Jianhui Wu,Yuji Wang,Ming Zhao (*)  , Shiqi Peng (*), Discovery of DEBIC to correlate P-selectin inhibition and DNA intercalation incancer therapy and complicated thrombosis,Oncotarget,2018,9(63),32119-32133 

2017 

Jianhui Wu, a§ Haimei Zhu, a§ Guodong Yang,a Yuji Wang, a Yaonan Wang, a Shurui Zhao,a Ming Zhao*a,b & Shiqi Peng*a, IQCA-TAVV: To get insight of the association between P-selectin, GPIIb/IIIa, IL-2, IL-6 and IL-8 into deep venous thrombosis. Oncotarget, 2017 , 8 (53) :91391-91401   

Jianhui Wu# , Haimei Zhu#, Ming Zhao, Yuji Wang ,Guodong Yang, Yaonan Wang, Shurui Zhao,Lin Gui,Xiaoyi Zhang,and Shiqi Peng. IQCA-TASS: A nano-scaled P-selectin inhibitor capable of targeting thrombus and releasing IQCA/TARGD(S)S in vivo, J. Mater. Chem. B, 2017, 5, 917—927  

Jianhui Wu, Ming Zhao, Yuji Wang, Yaonan Wang, Haimei Zhu, Shurui Zhao, Lin Gui, Xiaoyi Zhang, and Shiqi Peng*, N-(3-hydroxymethyl-β-carboline-1-yl-ethyl-2-yl)-l-Phe:development toward nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation, Drug design, development and therapy , 2017 , 11 :225-239  

Haiping Ma, Ming Zhao, Yuji Wang, Haimei Zhu, Yaonan Wang, Shurui Zhao, Jianhui Wu, Shiqi Peng    Cholyl-L-Lysine-carboxyl butyryl adriamycin produgs targeting chemically induced liver injury.      J. Mater. Chem. B , 2017,5, 470-478 

Xinyi Xu, Yuji Wang, Jianhui Wu, Xi Hu, Haimei Zhu, Xiaoyi Zhang, Yaonan Wang, Lin Gui, Ming Zhao, Shiqi Peng. ATIQCTPC: a nanomedicine capable of targeting tumor and blocking thrombosis in vivo. International Journal of Nanomedicine, 2017, 12: 4415 -4431  

Yuji Wang, Xinyi Xu, Ce Song, Jianhui Wu, Xi Hu, Haimei Zhu, Xiaoyi Zhang,Yaonan Wang, Lin Gui, Ming Zhao, and Shiqi Peng. ATIQCTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma in vivo. Oncotarget, 2017, 8, 38, 63881-63889  

Haimei Zhu, Yuji Wang, Ce Song, Qiqi Feng, Jianhui Wu, Shurui Zhao, Lin Gui, Xiaoyi Zhang, Ming Zhao and Shiqi Peng. Docking of THPDTPI: to explore P-selectin been a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent,\. Oncotarget, 2018 , 9 (1) :268 

Xiaozhen Wang , Yuji Wanga, Jianhui Wu, Lin Gui , Xiaoyi Zhang , Meiqing Zheng , Yaonan Wang, Shurui Zhao , Ze Li , Ming Zhao*, Shiqi Peng* .Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.Bioorganic & Medicinal Chemistry Letters 27 (2017) 5114–5118 

Haiyan Chen,Wenjing Wang,Xiaoyi Zhang,Shan Liu,Yaonan Wang,Haimei Zhu,Jianhui Wu,YujiWang,Ming Zhao (*)  , Shiqi Peng (*), Discovery of DEBIC to correlate P-selectin inhibition and DNA intercalation incancer therapy and complicated thrombosis,Oncotarget

2016

Taiping Gan, Yuji Wang, Ming Zhao, Jianhui Wu, Jian Yang, Shiqi Peng.,5-(Bis(3-(2-hydroxyethyl)- 1H-indol-2-yl)methyl)-2-hydroxybenzoic acid (BHI MHA ): showing a strategy of designing drug to block lung metastasis of tumors.Drug Design, Development and Therapy 2016, 10: 711-721.

Xi Hu, Ming Zhao, Yuji Wang, Yaonan Wang, Shurui Zhao, Jianhui Wu, Xiangmin Li and Shiqi Peng ,Tetrahydro-b-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications. J. Mater. Chem. B, 2016:4, 1384-1397.    

Xu Wenyun, Zhao Ming, Wang Yuji, Zhu haimei, Wang Yaonan, Zhao Shurui, Wu Jianhui, Peng Shiqi ,Design, synthesis, and in vivo evaluations of benzyl Nω-nitro-Nα-(9H-pyrido[3,4-b]indole-3-carbonyl)-L-argininate as an apoptosis inducer capable of decreasing the serum concentration of P-selectin. Medchemcomm, 2016, 7, 1730    

Ning Song,Ming Zhao,Yuji Wang,Xi Hu,Jianhui Wu,Xueyun Jiang,Shan Li,Chunying Cui,Shiqi Peng1 Nanomedical strategy to prolong survival period, heighten cure rate, and lower systemic toxicity of s180 mice treated with mtx/mit.. Drug Design Development & Therapy,2016, Volume 10, 2701-2711. 

Qiqi Feng, Ming Zhao*,Taiping Gan, Haimei Zhu, Yaonan Wang, Shurui Zhao, Yuji Wang, Jianhui Wu and Shiqi Peng*.DHDMIQK(KAP): a novel nano-delivery system of dihydroxyl-tetrahydro-isoquinoline-3-carboxylic acid and KPAK towards the thrombus.       Journal of Materials Chemistry B.  2016. 4. 5991-6003.    

Lv Xiaojie, Zhao Ming*, Wang Yuji, Hu Xi, Wu Jianhui, Jiang Xueyue, Li Shan, Cui Chunying, Peng Shiqi*.Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy.    Drug Design, Development and Therapy.  2016.  10.  3933-3946.       

Zhigang Zhao, Xingang Li, Shusen Sun,Shenghui Mei,Ning Ma,Zhongrong Miao,Ming Zhao* , Shiqi Peng*. Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.  European Journal of Clinical Pharmacology.  2016.  72(10).  1195-1204.     

Jianhui Wu, Ming Zhao, Yuji Wang, Yaonan Wang, Haimei Zhu, Shurui Zhao, Shiqi Peng, A novel lead of P-selectin inhibitor: Discovery, synthesis, bioassays and action mechanism. Bioorg Med Chem Lett, 2016, 26, 4631 - 4636

Haimei Zhu, Yuanbo Song, Yuji Wang, Ming Zhao, Yi Ren, Yaonan Wang, Shurui Zhao, Jianhui Wu and Shiqi Peng .Design, synthesis and evaluation of a novel π–π stacking nano-intercalator as an anti-tumor agent  MedChemComm. 2016, 7, 247-257  

xueyun jiang,ming zhao,haimei zhu,shurui zhao,yuanbo song,shiqi,peng .RGD(F/S/V)-Dex: towards the development of novel, effective, and safe glucocorticoids  Drug Design, Development and Therapy2016:10 1059-1076   

Yinghuan Li, Lei Gao, Xi Tan, Feiyang Li, Ming Zhao, Shiqi Peng .Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes   .Biochimica Biophysica Acta 2016, 1858 (8) : 1801–1811

主编或副主编的著作/译著

1.    Shiqi Peng, Ming Zhao. Pharmaceutical Bioassays. John Wiley. &Sons, Inc, 2009

2.    Shayne Cox Gad, Handbook of Pharmaceutical biotechnology (Chapter 5 Pharmaceutical Bioassays). John Wiley. &Sons, Inc.,2007

3.    彭师奇,《药物化学原理》,北京大学医学出版社,2006

4.    彭师奇,《预防药学》,北京大学医学出版社, 2003

5.    彭师奇,《新药的发现与发明》,山东科学技术出版社,2001

6.    彭师奇,《药物的波普解析》,北京大学医学出版社,1998

7.    彭师奇,《多肽药物化学》,科学出版社,1993

8.    彭师奇,于学敏,《光谱立体化学》,陕西科学技术出版社,1993

9.    彭师奇,赵明,Organic Chemistry,高等教育出版社,2012

10.  赵明,彭师奇,General Chemistry,高等教育出版社,2012

11. 赵明,彭师奇,骨质疏松症及多途径预防策略,高等教育出版社,2013

12. Ming Zhao,Yuji Wang,Jianhui Wu,Shiqi Peng,TOPICS IN OSTEOPOROSIS(Chapter 4),INTECH,2013

13. 彭师奇,赵明,《药物的波谱解析》,高等教育出版社,2014

重要奖项

1.北京市科技进步二等奖,2006

2.北京市特聘教授,2006

3.国务院政府津贴,2008

4.首都教育先锋科技创新先进个人,2009

5.北京市教育教学成果二等奖,2009

6.北京市三八红旗奖章荣誉称号,2010

7.北京市教育教学成果二等奖,2013

8.北京市教学名师,2015

9.北京市高层次创新创业人才支持计划领军人才

10..北京市优秀教师 2017

11.北京师德榜样 2018

12.首都劳动奖章 2019

 



字号: 打印
                           
版权所有:首都医科大学药学院
联系电话:010-83911532 传真:010-83911533 联系地址:北京市右安门外西头条10号 邮编:100069